Imagine if we could fix the genetic errors that cause debilitating diseases in your body. Recent breakthroughs in gene editing are making this a reality, and one company's trial results are showing just how powerful this technology can be.
Intellia Therapeutics (NTLA) stock surged over 50% after announcing groundbreaking clinical trial results.
This massive jump on June 26, 2021, highlighted investor excitement for their gene-editing therapy, NTLA-2001, which targets a rare genetic disease called ATTR amyloidosis.